Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Cancer research (2004) - Comments
doi: 10.1158/0008-5472.CAN-03-3500  pubmed: 15466208  issn: 0008-5472  issn: 1538-7445  pii: 64/19/7117 

Ali R. Jazirehi, Mario I. Vega, Devasis Chatterjee, Lee Goodglick, Benjamin Bonavida